This review highlights risk factors and treatment strategies for low-T2 asthma in children, indicating a need for improved care.
Type -2 (T2) low asthma in children represents a clinically important yet still insufficiently recognized endotype. Current data suggest that it is more prevalent than previously thought and is defined by low type 2 biomarkers, non-allergic clinical profiles, and a high burden of comorbidities such as obesity and passive smoke exposure, while remaining largely understudied phenotype in terms of validated biomarkers and specific targeted therapies. This review aims to highlight and clarify T2-low asthma in children by summarizing emerging evidence on risk factors, pathophysiological mechanisms, bi-omarkers, and treatment strategies, with the goal of informing and improving future care for affected children.
No takes yet. Share an insight, caveat, or question.
Kobal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: